Financial Architects, Inc Geron Corp Transaction History

Financial Architects, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 06, 2019	SELL	$1.15 - $1.59 $517 - $715	-450 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.37 - $2.02 $2,055 - $3,030	-1,500 Reduced 76.92%	450 $1,000
Q1 2019 May 13, 2019	BUY	$1.01 - $1.83 $1,969 - $3,568	1,950 New	1,950 $3,000
Q1 2019 May 03, 2019	SELL	$1.01 - $1.83 $1,969 - $3,568	-1,950 Closed	0 $0
Q4 2018 Feb 01, 2019	SELL	$0.98 - $1.85 $294 - $555	-300 Reduced 13.33%	1,950 $2,000
Q3 2018 Oct 29, 2018	BUY	$1.76 - $6.38 $792 - $2,871	450 Added 25.0%	2,250 $4,000
Q2 2018 Aug 03, 2018	SELL	$3.29 - $4.82 $822 - $1,205	-250 Reduced 12.2%	1,800 $6,000
Q3 2017 Nov 01, 2017	BUY	$1.99 - $2.65 $4,079 - $5,432	2,050	2,050 $4,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.